Genetic modifiers of p53 and their potential in breast cancer therapies
A new editorial perspective titled "Genetic modifiers of p53: opportunities for breast cancer therapies" has been published in Oncotarget.
Oct 25, 2023
0
0
A new editorial perspective titled "Genetic modifiers of p53: opportunities for breast cancer therapies" has been published in Oncotarget.
Oct 25, 2023
0
0
p53 is one of the most important proteins in cancer biology. Often referred to as a "guardian of the genome," p53 becomes activated in response to various cellular stressors like DNA damage. Its activation induces different ...
Jul 12, 2022
0
21
More children die of brain tumors than any other type of cancer. Diffuse midline gliomas (DMGs) are a particularly deadly kind, and are difficult to treat with drugs or surgery because they're in an important part of the ...
Feb 4, 2022
0
131
A protein that protects cells from DNA damage, p53, is activated during gene editing using the CRISPR technique. Consequently, cells with mutated p53 have a survival advantage, which can cause cancer. Researchers at Karolinska ...
Nov 18, 2021
0
6
A comprehensive study—conducted by researchers at Sanford Burnham Prebys, the National Cancer Institute (NCI) and other groups—has shown that gene editing, specifically gene knockout (KO), with CRISPR -Cas9 can favor ...
Nov 11, 2021
0
80
The tumor suppressor protein p53 is mutated in more than half of all human cancers. Several drugs that potentially can restore mutant p53 to its normal cancer-killing function are in clinical investigation.
Aug 31, 2021
0
108
Scientists at VCU Massey Cancer Center have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.
Apr 19, 2021
0
137
Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature ...
May 18, 2020
0
222
T cells targeting p53 hotspot mutations can be harvested from peripheral blood of patients with metastatic solid epithelial cancers, according to results published in Clinical Cancer Research, a journal of the American Association ...
Jan 29, 2020
0
12
More than half of cancer cases worldwide are associated with genetic mutations in p53, the protein responsible for protecting DNA from changes that can lead to cancer. When this protein deforms, it not only loses its protective ...
Jan 9, 2020
0
12